





Understanding Cancer Lecture 9 **Types of signalling** pathway: normal and dysregulated PLC-y1-PKC DR HAFSA WASEELA ABBAS www.hafsaabbas.com



RECAP:

What you hopefully should understand so far from Lecture 8

Following activation of EGFR or TKR, PI3K is activated.

PI3K consists of two subunits: p110-alpha catalytic subunit and p85 regulatory subunit.

p110 subunit produces the second messenger Phosphatidylinositol (3,4,5)-trisphosphate (PIP₃).

AKT is a serine-threonine kinase that is activated by PDK1 and mTORC2 effector protein.

mTORC1 signalling cascade is activated by phosphorylated AKT.

RAS can bind to PI3K by PI3K p110 subunit.

Inhibitors of AKT or mTOR increases expression and activity of growth factor receptors. This increases PI3K activity and RAS signalling. This correlates with advanced stage of the disease and/or poor prognosis.

Matrix metalloproteinases (MMPs) proteolytic enzymes are regulated by AKT. AKT expression knockdown affects mTOR. This downregulates mRNA of MMP2 and MMP9. This effects invasion and metastasis

What will we learn today?

The structure of phospholipase C (PLC)

Normal PLC-y1-PKC signalling pathway: Receptor activation

Normal PLC-y1-PKC signalling pathway: Signal transduction

Other types of signal transduction: phospholipase D (PLD).

Normal PLC-y1-PKC signalling pathway: Cellular response

The link between GPCR and PLC-y1-PKC signalling pathways

Causes of dysregulated PLC-y1-PKC signalling pathway in cancer



www.hafsaabbas.com

GENTLE REMINDER An ideal way of learning:

Monday Tuesday Wednesday Thursday Friday Saturday Sunday

Mini-lectures.

Approximate total time: 1 hour Divide over 7 days at your <u>own pace</u>. Challenge yourself with a quiz!



www.hafsaabbas.com

RECAP: How to support your learning?



Glossary to help understand what key words mean.



Summary doodle revision posters by HN designs.



Quizzes to test your knowledge and reflect.




Reference list for further reading.

Acknowledgements: Special thanks to my parents, family, friends and colleagues for their support and the respected teachers and health professions who taught me and installed the passion of cancer/oncology.

The structure and function of phospholipase C (PLC)

 There are 13 isozymes of PLC in mammals that are encoded by different genes.
 They, have been divided into 6 families

- They have been divided into 6 families based on structure, sequence and function.
- They are key signalling proteins in response to many molecules.



PLC isozyme	Subtypes	Function
ΡLCβ	1,2,3,4	 Cardiovascular and neuronal signaling. PLCβ2 negatively regulates iinflammatory responses induced by viruses. This prevents phosphoinositide from activating Transforming growth factor-β-activated kinase 1 (TAK1). TAK1 is a member of the mitogen-activated protein kinase kinase kinase (MAPKKK) family. TAK1 plays a part of NF-κB, c-Jun N-terminal kinase (JNK), and p38 pathways⁻

N-terminal	PH	EF	X	Y	C2	PDZ	C-terminal		
Name of PLCβ domain	Abbrev	viation F	unction						
pleckstrin homology	pleckstrin homology PH Regulatory protein domain involved in intracellular signalling.								
EF			A regulatory domain or motif with a helix–loop–helix structure that bind to calcium.						
X		C	atalytic do	main					
Υ		C	atalytic do	main					
C2			protein st ell membra		omain invol	ved in targ	eting proteins to		
PDZ-Binding Motifs	PBMs	S	caffolding	protein					
		lo	on channel	s and prote	eins cluste	red togethe	er at synapses in the		
		b	rain, photo	oreceptors	and epithe	lial cells.			

PLC isozyme	Subtypes	Function
ΡLCγ	1 and 2	 Effector enzymes for membrane-bound receptors in signal transduction pathways.
		e.g.
		It hydrolyses phosphatidylinositol-4, 5-bisphosphate (PI(4,5)P2) (PIP2)
		phospholipid in the membrane to produce the two second
		messengers:
		 Diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).
		Both stimulate the enzyme protein kinase C (PKC) for downstream
		signalling.
		PLC-γ1, the protein encoded by <i>Plcg1</i> .

N-terminal	PH	EF	X	PH	SH2	SH2	SH3	PH	Y	C2	C-terminal
Name of PL domain	С-ү	Abbrev	iation	Functio	n						
pleckstrin homology PH Regulatory protein domain involved in intracellular signalling.											
EF	EF A regulatory domain or motif with a helix-loop-helix structure that bind to calcium.						structure				
X				Catalyti	ic doma	in					
SH2				Interact	ting don	nains fo	r tyrosir	ne in rec	eptor ty	yrosine	kinase
SH3	SH3 It forms complex with other proteins which facilitates signal transduction.										
Υ				Catalyti	ic doma	in					
C2 A protein structural domain involved in targeting proteins to cell membranes.						teins to					

PLC isozyme	Subtypes	Function
ΡLCδ	1, 3 and 4	It is sensitive to calcium and activated by small increases of calcium concentration only.



Name of PLC- δ	Abbreviation	Function
domain		
pleckstrin homology	PH	Regulatory protein domain involved in intracellular signalling.
EF		A regulatory domain or motif with a helix–loop–helix structure
		that bind to calcium.
X		Catalytic domain
Υ		Catalytic domain
C2		A protein structural domain involved in targeting proteins to
		cell membranes.

PLC isozyme	Subtypes	Function
PLCε	1	 It is involved in the downstream-signalling events of G-protein
		coupled receptors (GPCRs).
		 They bind with RhoA and Rap1 to regulate PLCε activity.
		Rap1 binds via its RA2 domain.

N-terminal	Ras-GEF	PH	EF X	Y	C2	RA1	RA1	C-terminal
Name of PLCε domain	Abbreviation	Functio	n					
Ras guanine nucleotic exchange factor	de Ras-GEF	 F It is a domain found in the CDC25 family of guanine nucleotide exchange factors for Ras-like sm GTPases I.e Rap1A GTPase. Ras bind to GTP and GDP and can slowly hydrolyse GTP to GDP Ras-GEF is encoded by a Toll-like receptor (TLR)-inducible gene TLR are expressed by macrophages to engulf pathogens. Hydrolysis of phosphatidylinositol (PI) at the space between the membranes (perinuclear) and G membranes in heart muscle cells (cardiomyocytes) 						o GDP e gene TLR are expressed by
pleckstrin homology	PH	Regulat	ory protein	domain i	nvolved	in intracell	ular signall	ing.
EF		A regula	itory doma	in or motif	with a h	elix–loop–	helix struc	ture that bind to calcium.
x		Catalyti	c domain					
Y		Catalyti	c domain					
C2		A protein structural domain involved in targeting proteins to cell membranes.						to cell membranes.
RA1	Ras association domains to interact with muscle-specific A-kinase anchoring protein (mAKAP) at the perinuclear membrane, and bind to activated Rap1A and Ras proteins.							

PLC isozyme	Subtypes	Function
ΡLCζ	1	 It is a sperm protein. It triggers calcium ions that move back and forth (oscillations) in the eggs starts embryogenesis.



Name of PLC ζ	Abbreviation	Function
domain		
EF		A regulatory domain or motif with a helix-loop-
		helix structure that bind to calcium.
X		Catalytic domain
Υ		Catalytic domain
C2		A protein structural domain involved in targeting
		proteins to cell membranes.

PLC isozyme	Subtypes	Function
PLCη	1 and 2	 It is the most sensitive type of PLC to calcium.
		It is important during the formation and maintenance neurons in the brain
		postnatal (after birth).

N-terminal	PH	EF	X	Y	C2	PDZ	C-terminal		
Name of PLCη domain	Abbrev	viation F	unction						
pleckstrin homology	leckstrin homology PH Regulatory protein domain involved in intracellular signalling.								
EF			A regulatory domain or motif with a helix–loop–helix structure that bind to calcium.						
X		(atalytic do	main					
Υ		(atalytic do	main					
C2	A protein structural domain involved in targeting proteins to cell membranes.								
PDZ-Binding Motifs	PBMs	S	Scaffolding protein						
		l	on channel	s and prote	eins cluste	red togethe	er at synapses in the		
		k	orain, photo	oreceptors	and epithe	lial cells.			

Overview

All PLCs have the following:

- EF-hand domain
- C2 domain
- Catalytic X and Y autophosphorylation linkage domain

Normal PLC-γ1-PKC signalling pathway: Receptor activation


RECAP: The structure of EGFR receptor.

	Domain	Function
I _m	l.	It is rich with leucine residues and binds to the ligand.
Extra cellular Pomai in	II	It is rich with cysteine residues and contains a dimerization arm that interacts with another dimerization arm of another receptor to form a homodimer. This helps maintain EGFR signalling but does not make contact with the ligand.
Tel	ш	It is rich with leucine residues and binds to the ligand.
TV	IV	It is rich with cysteine residues and can form disulfide bonds to domain II,
TM Domain JM-A Domain JN-B Domain		and links to the transmembrane domain. It does not make contact with the ligand.
JH-B Domain	Transmembrane	It firmly attaches the receptor to the membrane and is involved in the
1.50		dimerization process.
Tyrosinekinase	C-terminal tyrosine kinase domain.	It has lots of tyrosine residues involved in phosphorylation (the addition of the phosphate group)
G-terminal		It has lots of lysine residues involved in ubiquitination (Ubiquitin is a small protein that directs proteins to the proteosome where proteins are
		degraded)

Step 1


The binding of the ligand to the EGFR receptor.

- The extracellular domain domains (I and III) to interact and bind with the ligand when the extracellular domain (II and IV) are pushed away.
- Each ligand specifically binds to a particular receptor.



The most common ligand is Epidermal
 Growth Factor (EGF) a growth factor
 protein is predominantly found in the
 heart, gut (intestines), brain, teeth,
 reproductive tracts and eyes.

It is involved in proliferation and differentiation.




<u>Step 2</u>

Dimerization of the receptor.

The dimerization arm in the extracellular domain II interacts with another dimerization arm of another to form a homodimer.

Heterodimerisationbetweenfamilymembers e.g.

EGF can induce heterodimerization of EGFR with HER2, HER3 or HER4.




<u>Step 3</u>

Receptor transautophosphorylation of C-terminal domain

The cytoplasmic domain of the intracellular region of one EGFR (N-lobe) contains tyrosine residues which phosphorylates the cytoplasmic domain of the intracellular region of the other EGFR (C-lobe).

This is known as

Transautophosphorylation.



Normal PLC-γ1-PKC signalling pathway: Signal transduction

Normal PLC-γ1-PKC signalling pathway: Signal transduction

phosphatidylinositol-3 kinase PI3K/Akt/mTOR


Ras/Raf/ MAPK/ERK PLC-γ phospholipase C gamma protein-PKC

JAK-STAT

Step 4

Formation of PI-bisphosphate (PIP₂).

Phosphatidylinositol(PI)isaphospholipidandisphosphorylatedbykinaseenzymestoformPI-phosphate(PIP)and PI-bisphosphate(PIP2).




<u>Step 5</u> PLC-γ1 binds to activated EGFR.

The SH2 domain of PLC-γ1(Phospholipase C gamma-1)binds directly to activated EGFR.

This occurs at the following tyrosine amino acid residues in EGFR:


□ Y992

□ Y1173




Step 6

The formation of the secondary messengers DAG and IP₃



PLC cleaves PIP_2 to form two second messengers: Diacylglerol (DAG) and Inositol triphosphate (IP_3).



The immunoreceptor tyrosinebased activation motif (ITAM) receptors expressed on T cells, natural killer cells, mast cells and platelets phosphorylate tyrosine residues in the intracellular domain of the transmembrane adapter LAT (linker for activation of T cells). The phosphorylated LAT recruits phospholipase C to

the receptor.


Other adaptor proteins are Grb2 and Gads/SLP-76 The phosphorylated PLCγ cleave the membrane lipid phophatidylinositol-4,5-bisphosphate (PIP2).

> PLCγ is phosphorylated by ZAP-70 or Syk proteins.

Did you know?

PI3Kβ adaptor protein phosphorylated to the receptor complex and binds to PIP₃

The PH domain of PLC- γ 1 binds to PIP₃ and recruited to the plasma membrane.




PLC-γ1 phosphorylated at Y472, Y771, Y778, Y783, and Y1254.

<u>Step 7</u>

Diacylglycerol (DAG) activates protein kinase C

Diacylglycerol (DAG) stays in the plasma membrane, binds and activates protein kinase C (PKC).




Step 8


The activated protein kinase C phosphorylates its target proteins

Protein kinase C phosphorylates serine and threonine amino acid residues in its target cellular proteins:

- **Cell** growth
- Differentiation
- Apoptosis



EGFR, RAF-1, H-RAS, p21, GSK-3 β , RHOA, BAD, and BCL-2.



DAG activates a number of PKC isoforms:


PKC α is phosphorylated by DAG at T497 residues

Isoform	Location
PKCα, βΙ, βΙΙ, δ, ε, η, ζ, and λ	Macrophages
PKCα, δ, ε, and ζ	TLR-induced inflammatory response
ΡΚϹθ	Macrophages but is undetectable. Lipopolysaccharide (LPS) and Interferon-gamma (IFNγ) can stimulate this form.

Did you know?

PKC can phosphorylate intracellular EGFR.


EGFR at T654 can block EGFinduced EGFR activation.




<u>Step 9</u>

IP₃ diffuses into the cytoplasm and *binds to the calcium ligand-gated channel in the endoplasmic reticulum membrane.*

 IP_3 diffuses into the cytoplasm and binds to IP_3 -receptors calcium channels in the endoplasmic reticulum membrane.






<u>Step 10</u>

Calcium channels open to release calcium ions.

The binding causes the calcium channels to open and release calcium ions into the cytoplasm.




<u>Step 11</u>

Calmodulin binds with calcium ions.

Calmodulin (CaM) is a protein whose role is to bind to calcium and regulate calcium-dependent pathways e.g.

The calcium-calmodulin complex activates enzymes and proteins that aid with cellular response

Carbohydrate breakdown in liver cells.



<u>Step 12</u>

Calcium ion is a secondary messenger and controls transcription factors

The increase of calcium ions can control the activation of transcription factors such as NFAT.

NFAT can bind to:

1) Forkhead box protein P3 (FOXP3) that regulates regulatory T cell expression.

Regulatory T cells are important for homeostasis where they halt the activation of leukocytes.

2) CNS2 is linked with the central nervous system in acute lymphoblastic leukemia (ALL).

ALL is a type of blood cancer that affects white blood cells.

The presence of leukaemia cells in the cerebrospinal fluid in the brain or spinal cord.

Blast cells are immature cells also known as stem cells.

Blasts can grow and differentiate into specialized cells e.g. neuroblasts give rise to nerve cells.

CNS disease can be divided based upon the number of blasts.

Type of CNS	Presence of blasts	Number of white blood cells
CNS1	Νο	< 5
CNS2	Yes	< 5
CNS3	Yes	<u>≥</u> 5

Other types of signal transduction: phospholipase D (PLD).

Phospholipase D (PLD).

PLD is phosphorylated by PKC at S2, T147, S561 residues Increase of PLD collaborates/synergises with EGFR and SRC to form a joint effort and contribute to fibroblast transformation.



PA interacts with proteins e.g. RAF, mTOR, S6K


PLD hydrolyses phosphatidylcholine to form phosphatidic acid (PA) and choline.

SRC

Classification	 11 non-receptor Src Family kinases: c-Src, Fyn, Yes, Blk, Yrk, Frk, Fgr, Hck, Lck, and Lyn. c-SRC, YES, and FYN are found in most tissues.
	 EGFR and HER4 have binding sites for SRC. The binding site of EGFR does not have an autophosphorylation site.
Function	 This is mediated by RAS and RAL. SRC negatively regulates RAS via phosphorylation. SRC positively regulates STAT (signal transducer and activator of transcription), EGFR, RAF, clathrin etc.


Cellular response

Cellular response



The link between GPCR and PLC

The link between GPCR and PLC



GPCR Pathway (Creative Commons, 2023)

When the ligand binds to the G protein coupled receptor activates to G protein

One of the isoforms of the alpha subunit of G-protein, $G\alpha q$, activates PLC and G12/13



PLC hydrolyses phosphatidylinositol 4,5biphosphate into diacylglycerol and inositol triphosphate



The causes of dysregulated PLC-γ1-PKC signalling pathway in cancer

The role of calcium ions in cancer

Angiogenesis

Sustained proliferative signaling

Invasion and metastasis

Evading apoptosis

Insensitivity to anti-growth signals

The role of PLC-y1-PKC in cancer

Initial tumour cell due to genetic changes (mutation)

BENIGN (A) GROWTH PLC-y1 facilitates cell MALIGNANT **(B)** migration, invasion and GROWTH metastasis in cancer. INVASION (C) **METASTASIS**

(D)

Blood vessel

The role of SRC in cancer

C-SRC mutation (Y845F) in SRC potentiates EGFR kinase activity without the need of a ligand. This helps increase tumour progression. Key examples: Head And Neck Squamous Cell Carcinoma Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer

By the end of this lecture, you should understand

- Phospholipase C-gamma (PLC-γ) is an adaptor protein that binds to the activated EGFR-EGF receptor complex.
- PLC- γ hydrolyses phosphatidylinositol-4, 5-bisphosphate (PI(4,5)P2) (PIP₂) phospholipid in the membrane

to produce the two second messengers: Diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP₃).

Diacylglycerol (DAG) stays in the plasma membrane, binds and activates protein kinase C (PKC).



 IP_3 diffuses into the cytoplasm and binds to IP_3 -receptors calcium channels in the endoplasmic reticulum membrane. The binding causes the calcium channels to open and release calcium ions into the cytoplasm.

PKC phosphorylates its target cellular proteins: cell growth, differentiation and apoptosis.



Mutation in PLC causes various hallmarks of cancer: angiogenesis, evade apoptosis, migration, invasion and metastasis.

Arneson, L.N. and Leibson, P.J. (2005). Signaling in Natural Immunity: Natural Killer Cells. *NeuroImmune Biology*, 5, pp.151–166.

Bentley, A. and Rety, S. (2000). EF-hand calcium-binding proteins. *Current Opinion in Structural Biology*, [online] 10(6), pp.637–643.

Cockcroft, S. (2006). The latest phospholipase C, PLCη, is implicated in neuronal function. *Trends in Biochemical Sciences*, 31(1), pp.4–7.

Dusaban, S.S. and Brown, J.H. (2015). PLCε mediated sustained signaling pathways. *Advances in Biological Regulation*, 57, pp.17–23.

Hachem, A., Godwin, J., Ruas, M., Lee, H.C., Ferrer Buitrago, M., Ardestani, G., Bassett, A., Fox, S., Navarrete, F., de Sutter, P., Heindryckx, B., Fissore, R. and Parrington, J. (2017). PLCζ is the physiological trigger of the Ca2+oscillations that induce embryogenesis in mammals but conception can occur in its absence. *Development*, 144(16), pp.2914–2924.

Johnston, Donna L. and Alonzo, Todd A. and Gerbing, Robert B. and Lange, Beverly J. and Woods, William G. (2010) 'The Presence of Central Nervous System Disease at Diagnosis in Pediatric Acute Myeloid Leukemia Does Not Affect Survival: A Children's Oncology Group Study' *Pediatric Blood Cancer* 55(3) pp. 414–420.

Kim, J.M. (2010). Molecular Mechanisms of Regulatory T Cell Development and Suppressive Function.

Progress in Molecular Biology and Translational Science, 92, pp.279–314.

Leãõ, F.B., Vaughn, L.S., Bhatt, D., Liao, W., Maloney, D., Carvalho, B.C., Camilo, L., Ghosh, S. and Silva, A.M. (2020). Toll-like Receptor (TLR)-induced Rasgef1b expression in macrophages is regulated by NF-κB through its proximal promoter. *The International Journal of Biochemistry & Cell Biology*, 127, pp.105840–105840.

Lu, L., Barbi, J. and Pan, F. (2017). The regulation of immune tolerance by FOXP3. *Nature Reviews Immunology*, [online] 17(11), pp.703–717.

Meng, L., Song, Z., Liu, A., Dahmen, U., Yang, X. and Fang, H. (2021). Effects of Lipopolysaccharide-Binding Protein (LBP) Single Nucleotide Polymorphism (SNP) in Infections, Inflammatory Diseases, Metabolic Disorders and Cancers. *Frontiers in Immunology*, 12.

Nakahara, M., Shimozawa, M., Nakamura, Y. Irino, Y., Morita, M., Kudo, Y. and Fukami, K. (2005)'A Novel Phospholipase C, PLCn2, Is a Neuron-specific Isozyme' *Journal of Biological Chemistry*, 280 (32) pp. 29128-29134.

Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Carotenuto, A., De Feo, G., Caponigro, F. and Salomon, D.S. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene*, [online] 366(1), pp.2–16.

Pecorino, L. (2012) '*Molecular Biology of Cancer Mechanisms, Targets, and Therapeutics*' UK: Oxford University Press

Protein Hardware for Signaling. (2017). *Elsevier eBooks*, pp.425–442.

Rakhmanov, M. (2005) Analysis of B lymphocyte activation and differentiation by expression profiling [Available online]

https://www.researchgate.net/publication/29756778_Analysis_of_B_lymphocyte_activation_and_differentiation_on_by_expression_profiling

Ramos, K S, and Weber. T. "Introduction and Overview of Alterations in Cell Signaling." *Comprehensive*

Toxicology, 2, pp. 447–471.

Raymaakers, K. (2023) 'Blast Cells and Myeloblasts Overview: High cell counts may be an indication of disease' Available [online] <u>https://www.verywellhealth.com/overview-of-blast-cells-4114662</u>

Rugema, N.Y., Garland-Kuntz, E.E., Sieng, M., Muralidharan, K., Van Camp, M.M., O'Neill, H., Mbongo, W., Selvia, A.F., Marti, A.T., Everly, A., McKenzie, E. and Lyon, A.M. (2020). Structure of phospholipase Cɛ reveals an integrated RA1 domain and previously unidentified regulatory elements. *Communications Biology*, [online] 3(1), pp.1–10.

Ubeysinghe, S., Wijayaratna, D., Kankanamge, D. Karunnarathne, A. (2023) "Molecular Regulation of PLCβ

Signaling." *Methods in Enzymology*, 682, pp. 17–52.

Wang, Lin, Zhou, Y., Chen, Z., Sun, L., Wu, J., Li, H., Liu, F., Wang, F., Yang, C., Yang, J., Leng, Q., Zhang,

Q., Xu, A., Shen, L., Sun, J., Wu, D., Fang, C., Lu, H., Yan, D. and Ge, B. (2022) "PLCβ2 Negatively

Regulates the Inflammatory Response to Virus Infection by Inhibiting Phosphoinositide-Mediated

Activation of TAK1." Nature Communications, 10 (1).

Wee, P. and Wang, Z. (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers*, 9(12), p.52.

Wonerow, P. and Watson, S.P. (2001). The transmembrane adapter LAT plays a central role in immune receptor signalling. *Oncogene*, 20(44), pp.6273–6283.

Zhu, L., Jones, C. and Zhang, G. (2018). The Role of Phospholipase C Signaling in Macrophage-Mediated Inflammatory Response. *Journal of Immunology Research*, [online] 2018(2), p.5201759.







Understanding Cancer Lecture 10 **Types of signalling** pathway: Transforming growth factor β (TGF- β) DR HAFSA WASEELA ABBAS www.hafsaabbas.com

